In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
The FDA Wants to Hear From You at OCRA’s Online Conference
Submit Your Questions for the FDA Listening Session On September 16–17, Ovarian Cancer Research Alliance (OCRA) will host the International Gynecologic Cancer Conference®, the largest conference dedicated to the gynecologic cancer community. Day 2 features a special opportunity: a Listening Session with leaders from the U.S. Food and Drug Administration (FDA). Ask questions about the FDA’s … Continued
September is Gynecologic and Ovarian Cancer Awareness Month
About Gynecologic and Ovarian Cancer Awareness Month September is recognized nationwide as Gynecologic and Ovarian Cancer Awareness Month, a dedicated time to raise awareness for all gynecologic cancers. Throughout the month, OCRA joins forces with patients, caregivers, and supporters to amplify our voices. We focus on educating the public about risks and symptoms, highlighting the … Continued
The Overview: July 2026
SummeRun Raises $260,000+ for Research, Hope and Progress Nearly one thousand runners, walkers, survivors, families, friends, and supporters showed up at Seattle’s Seward Park on Sunday, July 12th, for the 33rd annual Ovarian Cancer Research Alliance (OCRA) Rivkin Family SummeRun, raising more than $260,000 for research and programs that support the gynecologic cancer community. The … Continued